JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL
A2412 CP-724714

Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R

Summary: HER2 inhibitor,potent and selective

≥23.5 mg/mL
A2822 AC480 (BMS-599626)

Target: EGFR

Summary: HER1/2 inhibitor,selective and efficacious

≥28.35 mg/mL
A1778 Vatalanib (PTK787) 2HCl

Target: VEGFR

Summary: Tyrosine kinase receptor inhibitor

≥21 mg/mL
A8322 Neratinib (HKI-272)
1 Citation

Target: EGFR

Summary: HER2/EGFR inhibitor,potent and irreversible

insoluble in H2O; ≥13.93 mg/mL
B4899 BLZ945
1 Citation

Target: CSF-1R

Summary: CSF-1R kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL